Hereditary/Familial Ovarian Cancer: Testing Principles and Risk Management
Studies suggest a benefit of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk in carriers of a BRCA1/2 pathogenic/likely pathogenic (P/LP) variant, but the magnitude of the effect is not well-understood, and evidence is mixed regarding age at which RRSO should be undertaken and the specific P/LP variant (BRCA1 vs. BRCA2) carried. More data are needed regarding the efficacy of salpingectomy without oophorectomy in reducing the risk for ovarian cancer in carriers of a BRCA1/2 P/LP variant.
Category
  • Ovarian Cancer
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Management of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
The treatment landscape for ovarian, fallopian tube, and primary peritoneal cancers has significantly evolved in recent years due to new FDA approvals and emerging clinical data on available targeted therapies. Continuing education is, therefore, essential for clinicians to stay informed about the efficacy and safety data for these systemic therapy options.
Category
  • Ovarian Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation